跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
REBLOZYL luspatercept 25 mg powder for injection vial - TGA Drug Approval Details
Approvals
/
TGA
/
REBLOZYL luspatercept 25 mg powder for injection vial
Approved
STANDARD
REBLOZYL luspatercept 25 mg powder for injection vial
Bristol-Myers Squibb Australia Pty Ltd
🇦🇺 Therapeutic Goods Administration
Approval Date
May 29, 2025
Approval ID
8f5f74b1fa85e07d
Company
Bristol-Myers Squibb Australia Pty Ltd
Type
Standard
Approval Details
Approval Id
8f5f74b1fa85e07d
Product Name
REBLOZYL luspatercept 25 mg powder for injection vial
Artg Id
334510
Artg Name
REBLOZYL luspatercept 25 mg powder for injection vial
Sponsor
Bristol-Myers Squibb Australia Pty Ltd
Company Detail Path
/organization/bristol-myers-squibb-australia-pty-ltd
Artg Date
2021-08-30
Registration Type
Medicine
Therapeutic Good Type
Medicine
Licence Status
A
Licence Category
RE
Active Ingredients
Approved
Quick Info
Agency
TGA
Country
🇦🇺
Approval Date
May 29, 2025
Approval ID
8f5f74b1fa85e07d
Type
Standard
Back to TGA Approvals
